Glaucoma drug Roclatan shows superior efficacy in late-stage study

Aerie Pharmaceuticals has reported successful efficacy results for the phase III Mercury 2 trial on Roclatan, a fixed dose combination of Rhopressa (netarsudil ophthalmic solution, 0.02%) and latanoprost for treatment of elevated IOP.
[Read More …]
Source: Daily Dose of Eye Care

Please follow and like us:
RSS
Facebook
Facebook
Google+
Google+
https://www.lvcenter4sight.com/glaucoma-drug-roclatan-shows-superior-efficacy-in-late-stage-study/

© Copyright Lehigh Valley Center For Sight